Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01973868 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01973868 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 42 participants.
The verdict
NCT01973868, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
To establish safety, tolerability and pharmacokinetics of regorafenib and cetuximab in combination, and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)
Interventions
- DRUG Regorafenib (Stivarga, BAY73-4506)
- DRUG Cetuximab (ERBITUX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-11-21 |
| Est. Completion | 2018-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01973868
The ClinicalTrials.gov registry entry for NCT01973868 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regorafenib (Stivarga, BAY73-4506) is the first listed.
NCT01973868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01973868 about?
NCT01973868 is a clinical study titled "Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination". To establish safety, tolerability and pharmacokinetics of regorafenib and cetuximab in combination, and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)
What is the current status of trial NCT01973868?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2013-11-21. Estimated completion is 2018-04-03.
What interventions are being tested in trial NCT01973868?
The interventions under investigation include: Regorafenib (Stivarga, BAY73-4506) (DRUG), Cetuximab (ERBITUX) (DRUG).
Who is sponsoring clinical trial NCT01973868?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.